ARCT

Arcturus Therapeutics Holdings Inc.

Pharmaceutical Preparations · SIC 2834CIK 1768224Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$82.0M

Net Income FY2025

$(66.0M)

EPS (Basic, as reported)

$-2.40

Net Margin FY2025

-80.2%

ROE FY2025

-30.7%

Total Equity

$214.0M

Shares Out

28M

Business description

Arcturus Therapeutics Holdings Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2018–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 16 → 82 +26.3% CAGR

Fiscal yearFY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue1621101220616715282

Research & development(17)(34)(58)(174)(148)(192)(195)(112)

General & administrative(21)(13)(23)(41)(46)(53)(53)(46)

Total operating expenses(38)(46)(81)(215)(194)(245)(248)(158)

Operating income(22)(26)(72)(203)12(78)(96)(76)

Other income (expense), net000(2)0171510

Pre-tax income(22)(26)(72)(204)11(28)(81)(66)

Income tax expense————(1)(2)0—

Net income(22)(26)(72)(204)9(30)(81)(66)

EPS — basic———($7.74)$0.35($1.12)($3.00)($2.40)

EPS — diluted———($7.74)$0.35($1.12)($3.00)($2.40)

Shares outstanding — basic (M)———2626272727

Shares outstanding — diluted (M)———2627272727

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.